PMID- 38196473
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240111
IS  - 1682-024X (Print)
IS  - 1681-715X (Electronic)
IS  - 1681-715X (Linking)
VI  - 40
IP  - 1Part-I
DP  - 2024 Jan-Feb
TI  - Efficacy of metformin combined with liraglutide on the glucose and lipid 
      metabolism, vascular endothelial function, and oxidative stress of patients with 
      T2DM and metabolic syndrome.
PG  - 26-30
LID - 10.12669/pjms.40.1.7936 [doi]
AB  - OBJECTIVE: This study evaluates the impact of metformin combined with liraglutide 
      on the glucose and lipid metabolism, oxidative stress, and vascular endothelium 
      of patients with type-2 diabetes mellitus (T2DM) and metabolic syndrome. METHODS: 
      Medical records of 78 patients with T2DM and metabolic syndrome, admitted to 
      Caoxian People's Hospital from July 2021 to July 2022, were retrospectively 
      analysed. Thirty five patients were treated with metformin (control group), and 
      43 patients were treated with metformin combined with liraglutide (observation 
      group). Indexes of glucose and lipid metabolism, function of vascular endothelium 
      and the oxidative stress of both groups were compared before and after the 
      treatment. RESULTS: There was a significant decrease in the levels of fasting 
      plasma glucose (FPG), Glycosylated Hemoglobin A1c (HbA1c), triglyceride (TG), 
      total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), systolic 
      blood pressure (SBP), diastolic blood pressure (DBP) and waist circumference in 
      both groups three months after the treatment, These indexes were significantly 
      lower in the observation group compared to the control group (P<0.05). 
      High-density lipoprotein cholesterol (HDL-C) levels were higher in the 
      observation group (P<0.05). There was a significant improvement in the levels of 
      nitric oxide (NO), endothelin-1 (ET-1), superoxide dismutase (SOD), and 
      malondialdehyde (MDA) after the treatment, and these indexes were markedly better 
      in the observation group compared to the control group (P<0.05). CONCLUSIONS: 
      Metformin combined with liraglutide treatment is associated with better outcomes 
      than metformin alone in patients with T2DM and metabolic syndrome. Combined 
      treatment results in improved glucose and lipid metabolism, vascular endothelial 
      function, and oxidative stress index values.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Liu, Zaisheng
AU  - Liu Z
AD  - Zaisheng Liu Department of Endocrinology Caoxian People's Hospital Cao Country, 
      Heze City, Shandong Province 274400, P.R. China.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC10772425
OTO - NOTNLM
OT  - Glucose and lipid metabolism
OT  - Metabolic syndrome
OT  - Metformin
OT  - Oxidative stress Liraglutide
OT  - Type-2 diabetes
OT  - Vascular endothelial function
EDAT- 2024/01/10 06:41
MHDA- 2024/01/10 06:42
PMCR- 2024/01/01
CRDT- 2024/01/10 03:35
PHST- 2023/03/20 00:00 [received]
PHST- 2023/03/30 00:00 [revised]
PHST- 2023/07/11 00:00 [revised]
PHST- 2023/07/23 00:00 [accepted]
PHST- 2024/01/10 06:42 [medline]
PHST- 2024/01/10 06:41 [pubmed]
PHST- 2024/01/10 03:35 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - PJMS-40-26 [pii]
AID - 10.12669/pjms.40.1.7936 [doi]
PST - ppublish
SO  - Pak J Med Sci. 2024 Jan-Feb;40(1Part-I):26-30. doi: 10.12669/pjms.40.1.7936.